PubRank

Anthony T Reder

Author PubWeight™ 32.70‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol 2011 3.52
2 Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler 2004 2.21
3 Evidence-based medicine: promise and pitfalls. Mult Scler 2012 2.07
4 Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010 1.37
5 Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J Neuroimmunol 2002 1.18
6 Brief International Cognitive Assessment for MS (BICAMS): international standards for validation. BMC Neurol 2012 1.18
7 Therapeutic role of beta-interferons in multiple sclerosis. Pharmacol Ther 2005 1.13
8 Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology 2013 1.12
9 Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry 2011 1.09
10 Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis. J Neurol Sci 2011 1.06
11 Cystoid macular edema associated with fingolimod use for multiple sclerosis. JAMA Ophthalmol 2013 1.02
12 Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study. BMJ Open 2012 1.00
13 Homonymous hemimacular thinning: a unique presentation of optic tract injury in neuromyelitis optica. J Neuroophthalmol 2012 0.99
14 IFN-beta-regulated genes show abnormal expression in therapy-naïve relapsing-remitting MS mononuclear cells: gene expression analysis employing all reported protein-protein interactions. J Neuroimmunol 2008 0.95
15 Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS. PLoS One 2011 0.92
16 Fingolimod for the treatment of relapsing multiple sclerosis. Expert Rev Neurother 2010 0.91
17 Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study. Clin Ther 2009 0.89
18 4-Aminopyridine toxicity mimics autoimmune-mediated limbic encephalitis. Neurology 2009 0.88
19 Multiple sclerosis. Part I: neuro-ophthalmic manifestations. Curr Opin Ophthalmol 2009 0.88
20 Adeno-associated viral vector-mediated ApoE expression in Alzheimer's disease mice: low CNS immune response, long-term expression, and astrocyte specificity. Front Biosci 2004 0.86
21 Inhibition of interferon-beta responses in multiple sclerosis immune cells associated with high-dose statins. Arch Neurol 2012 0.85
22 Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command. Curr Med Res Opin 2009 0.85
23 Interferonβ-1b Induces the Expression of RGS1 a Negative Regulator of G-Protein Signaling. Int J Cell Biol 2011 0.85
24 Type I interferons inhibit interleukin-10 production in activated human monocytes and stimulate IL-10 in T cells: implications for Th1-mediated diseases. J Interferon Cytokine Res 2002 0.84
25 Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b. Mult Scler 2009 0.83
26 Induction of a unique isoform of the NCOA7 oxidation resistance gene by interferon β-1b. J Interferon Cytokine Res 2014 0.81
27 MxA: a biomarker for predicting multiple sclerosis disease activity. Neurology 2010 0.80
28 Anti-myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis. Neurology 2004 0.79
29 Treatment with interferon beta for multiple sclerosis. JAMA 2012 0.77
30 Response to GS Gronseth and E Ashman. Mult Scler 2012 0.76